TMC Looks To Add cSSSI Drug, Antibiotic Capabilities With Targanta Offer
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed merger would see The Medicines Company take over development of oritavancin, stalled at FDA due to “complete response” letter.